



DEPARTMENT OF JUSTICE
DRUG ENFORCEMENT ADMINISTRATION
MANUFACTURER OF CONTROLLED SUBSTANCES
NOTICE OF APPLICATION
NEKTAR THERAPEUTICS

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on August 16, 2013, Nektar Therapeutics, 1112 Church Street, Huntsville, Alabama 35801, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Fentanyl (9801), a basic class of controlled substance listed in schedule II.

The company plans to manufacture the listed controlled substance in support of product development.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR § 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODW), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than [INSERT DATE 60 DAYS FROM DATE OF PUBLICATION].

Joseph T. Rannazzisi
Deputy Assistant Administrator
Office of Diversion Control
Drug Enforcement Administration

DATED: September 27, 2013

[FR Doc. 2013-25079 Filed 10/24/2013 at 8:45 am; Publication Date: 10/25/2013]